Breas Vivo 3, Руководство для клиницистов

Страница: 126 / 143

Immunity test IEC 60601 test level Recommended separation distance
Conducted RF
IEC 61000-4-6 3 V
rms
(6 V
rms
inside
ISM/ASR bands)
d=0.35* √ P m at 150 kHz to 80 MHz
Radiated RF
IEC 61000
‑ 4 ‑ 3
10 V/m 80 MHz to
2.7 GHz
d= 0.6* √ P m at 80 MHz to 800 MHz
d= 1.2*
√
P m at 800 MHz to 2.5 GHz
Equation description: P is the maxi-
mum output power rating of the transmit-
ter in watts (W) according to the
transmitter manufacturer and d is the rec-
ommended separation distance in metres
(m).
Field strengths from fixed RF transmitters,
as determined by an electromagnetic site
survey
a
, should be less than the compli-
ance level in each frequency range b .
Interference may occur in the vicinity of
equipment marked with this symbol.
• At 80 MHz and 800 MHz, the higher frequency range applies.
•
These guidelines may not apply in all situations. Electromagnetic propagation is
affected by absorption and reflection from structures, objects and people.
a) Field strengths from fixed transmitters, such as base stations for radio (cellular/cord-
less) telephones and land mobile radios, amateur radio, AM and FM radio broadcast and
TV broadcast cannot be predicted theoretically with accuracy. To assess the electromag-
netic environment due to fixed RF transmitters, an electromagnetic site survey should
be considered. If the measured field strength in the location in which the Vivo 3 is used
exceeds the applicable RF compliance level above, the Vivo 3 should be observed to
verify normal operation. If abnormal performance is observed, additional measures may
be necessary, such as reorienting or relocating the Vivo 3.
b) Over the frequency range 150 kHz to 80 MHz, field strengths should be less than 10
V/m.
9.7.2 Guidance and Manufacturer's Declaration
–
Electromagnetic Emission
The Vivo 3 are intended for use in the electromagnetic environment specified below.
The customer or the user of the Vivo 3 should assure that it is used in such an
environment.
126 Technical Specifications
Vivo 3 Clinician
’
s Manual
Doc. 007232 Y-2